Myelodysplastic syndrome (MDS) is a heterogeneous bone marrow disorder primarily affecting older adults, for whom the only curative therapy, bone marrow transplantation, is rarely an option. New therapies, or novel applications of historical therapies, are desperately needed. Arsenic trioxide (ATO), which acts through proapoptotic, antiproliferative, and antiangiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. As monotherapy or in combination with other agents, it can effect hematologic improvement in 22% to 26% of patients, with tolerable side effects. MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy.
"Lenalidomide , an immunomodulatory drug derived from thalidomide , has been recently approved by the Food and Drug Administration ( FDA ) and is indicated for the treatment of MDS in patients with chromosome 5q deletion . Other agents such as imatinib and tipifarnib are currently being evaluated in clinical trials ( Cortes et al 2003 ; Feldman 2005 ; Sekeres 2005 ; Jabbour and Giles 2005 ) . Some of the therapies farthest along in development are the hypomethylating agents decitabine and azacitidine , both of which have been recently approved by the FDA for the treatment of MDS . "
[Show abstract][Hide abstract] ABSTRACT: Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias and a propensity to transform into acute myeloid leukemia. There are few treatment options available for patients with MDS. Studies into the molecular biology of MDS have demonstrated abnormal patterns of DNA methylation that lead to silencing of tumor-suppressor genes. Hypomethylating agents are compounds that have the potential to reverse the aberrant DNA methylation and increase the expression of silenced genes, leading to cellular differentiation and/or apoptosis. Decitabine is a cytidine analogue that has activity as a hypomethylating agent and has been evaluated in the therapy of patients with high-risk MDS. Several studies have confirmed the clinical activity of low-dose decitabine in patients with high-risk MDS, leading to responses in approximately 50% of patients, with low treatment-related mortality. Responses have even been seen in patients with high-risk cytogenetic abnormalities, and some studies have demonstrated increased re-expression of genes that were previously silenced by hypermethylation, such as CDKN2B/p15INK4B. There are still some issues concerning the ideal dose and schedule of decitabine for treating patients with MDS. This article focuses on the most recent clinical studies of decitabine for therapy of MDS.
[Show abstract][Hide abstract] ABSTRACT: This work presents a compartmental model for delivery of three drugs (isoflurane, dopamine and sodium nitroprusside) for regulation of anesthesia. The key feature of this model is that mean arterial pressure, cardiac output and unconsciousness of the patient can be simultaneously regulated. This model is ‘validated’ by carrying out a number of dynamic state simulations and then used for designing model based parametric controllers.
Computer Aided Chemical Engineering 01/2005; 20. DOI:10.1016/S1570-7946(05)80011-2
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.